Safety and immunogenicity of a booster dose of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre trial.
Hum Vaccin ImmunotherJun 10, 2026 (epub)
Glenn Hamonic, Supriya Arora, Ravendra Garg et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase 1 randomized controlled trial assessed the safety and immunogenicity of the COVAC-2 vaccine as a heterologous booster in 60 previously vaccinated adults. The 25 µg dose demonstrated the strongest immune response, with peak antibody titers observed 14 days post-vaccination and sustained above baseline through Day 180. No serious adverse events were reported.
Key findings
- The 25 µg dose of COVAC-2 elicited the strongest humoral and cellular immune responses.
- Peak antibody titers were observed 14 days after vaccination.
- Immune responses were sustained above baseline levels through Day 180.
- No serious adverse events were attributed to the vaccination.
Why it matters
Understanding the safety and immunogenicity of booster vaccines is crucial for enhancing population immunity against COVID-19, particularly in the context of emerging variants and the need for effective vaccination strategies worldwide.